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AbstrAct
Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with frequent 
metastatic rate and poor survival. Integrated analyses allow understanding the 
interplay between different levels of molecular alterations.
We integrated miRNA and gene expression data from 458 ccRCC and 254 normal 
kidney specimens to construct a miRNA-target interaction network.
We identified the downregulated miR-124-3p, -30a-5p and -200c-3p as the most 
influential miRNAs in RCC pathogenesis.miR-124-3p and miR-200c-3p expression 
showed association with patient survival, miR-30a-5p was downregulated in 
metastases compared to primary tumors. We used an independent set of 87 matched 
samples for validation. We confirmed the functional impact of these miRNAs by in vitro 
assays. Restoration of these miRNAs reduced migration, invasion and proliferation. 
miR-124-3p decreased the S phase of cell cycle, as well. We compared transcriptome 
profiling before and after miRNA overexpression, and validated CAV1 and FLOT1 as 
miR-124-3p targets. Patients with higher CAV1 and FLOT1 had lower miR-124-3p 
expression and shorter overall survival.
We hypothesize that these three miRNAs are fundamental contributing to ccRCC 
aggressive/metastatic behavior; and miR-124-3p especially has a key role through 
regulating CAV1 and FLOT1 expression. Restoration of the levels of these miRNAs 
could be considered as a potential therapeutic strategy for ccRCC.
IntroductIon
Kidney cancer is a common urologic malignancy 
and its incidence has been steadily rising by 2–4% each 
year [1]. The vast majority of adult kidney cancers are 
renal cell carcinomas (RCC), and 70-85% of those are 
clear cell subtype (ccRCC) [2]. Around 30% patients are 
already at metastatic stage at the time of diagnosis even 
in the absence of symptoms [1]. Patients with metastatic 
disease have 13 months median survival and the 5 year 
survival rate under 10% [3]. MicroRNAs (miRNAs) are 
small, protein non-coding RNA molecules which post-
transcriptionally regulate protein expression. Their role 
have been broadly investigated and demonstrated in 
several cancers including ccRCC [4].
Results of different studies for miRNA expression 
profiling in ccRCC show significant variations [5]. In 
order to overcome this obstacle, literature suggest that 
combining multiple datasets is more informative than 
considering them individually [6]. Is has also been 
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suggested that increasing the number of replicates adds 
robustness to the experimental design and limits the 
undesired effects and bias in expression profiles, especially 
when comparing different platforms [7]. More recently, 
“integrated genomics” which compiles information from 
multiple levels of molecular changes, holds the promise of 
providing a better understanding of the interplay between 
molecular alterations [8].
In order to gain better understanding of the complex 
functional impact of miRNAs in ccRCC pathogenesis, we 
cross-matched miRNA and gene expression data from 458 
ccRCC and 254 normal kidney specimens to construct a 
miRNA-target interaction network that can better reveal 
the involvement of miRNAs in kidney cancer. We further 
filtered our data by performing tissue-specific target 
prediction [9]. We identified the three most influential 
miRNAs in ccRCC and investigated their role by in 
vitro functional assays. We experimentally validated our 
results on independent sets of cases. We also confirmed 
the functional impact of these miRNAs by in vitro assays 
using cell line models. Comparing transcriptome profiling 
before and after miRNA overexpression, combined with 
pathway and gene ontology analysis, we identified critical 
targets and miRNA-mediated pathways with correlation to 
survival in ccRCC.
results
construction of mirnA network of ccrcc
Using the previously identified most common gene 
and miRNA alterations in ccRCC compared to normal 
kidney [10], we performed tissue-specific target prediction 
analysis. We identified 600 miRNAs-mRNA interaction 
pairs that consist of 49 miRNAs and 266 genes. In order 
to zoom in specifically to the involvement of miRNAs in 
ccRCC pathogenesis, we further filtered the target genes 
for the term “RCC associated genes” using Ingenuity 
Knowledge Database (Supplementary Table 1). Using 
these filtered interaction pairs we built multiple 35-node 
networks that are characteristic to RCC by functional 
annotation (Supplementary Table 2). We then merged 
Figure 1: mirnA-target network of ccrcc. Organic plot of miRNA-target network of ccRCC. Node’s colour and size represents 
the number of interaction (node degree); edge’s colour and size indicates the significance of interactions (edge betweeness).
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the top three networks to obtain a 133-node miRNA 
network including 20 miRNAs and RCC-associated 
genes using Ingenuity Pathway Analysis Software.The 
network structure is formed of basic elements (genes and 
miRNAs; named nodes) and the connections representing 
miRNA-target interactions (named edges) (Figure 1). Our 
results show that miRNA effect on RCC has “divergent” 
properties where the same miRNA targets multiple 
genes. It is also “convergent” in nature, where multiple 
miRNAs have augmented effect on the same target. The 
most significant miRNAs (nodes with highest number of 
interactions) were miR-200c-3p, miR-124-3p and miR-
30a-5p possessing the most connections, each having 7-9 
targets (Table 1).
experimental tissue validation and the potential 
significance of miR-124-3p, miR-200c-3p, and 
miRNA-30a-5p in ccRCC aggressiveness
All three miRNAs were downregulated in our 
analysis. We validated the dysregulation of these miRNAs 
and as it is shown in Figure 2, all three miRNAs were 
found to be downregulated in ccRCC compared to normal 
kidney.
Table 1: miR-124-3p, miR-30a-5p andmiR-200c-3p targets in ccRCC miRNA network.
mirnA name # of targets target gene name
miR-200c-3p 9 CDH6, CREBBP, FLT1, FN1, KDR, PPM1F, TIPM2, TUBB, VEGFA
miR-30a-5p 7 IFNAR2, KDELC2, LRRC8C, MET, TIMP2, TNFSF9, TP53
miR-124-3p 7 AHRR, CAV1, DRAM1, GAS2L1, GNA13, PPM1F, SLC1A4
Figure 2: miR-124-3p, -30a-5p and -200c-3p expression in ccRCC and miRNA expression association with patient 
survival. A: miR-124-3p, -30a-5p and -200c-3p are downregulated in ccRCC with -2.46, -1.41 and -9.39 fold change, respectively (p < 
0.001) compared to normal kidney. NNormal: 66, NccRCC: 499 – data were extracted from TCGA dataset. b: Survival analysis performed on 
our independent patient set of 62 ccRCCs. Patients having lower miR-124-3p or higher miR-200c-3p expression have worse disease-free 
and overall survival. There was no significant association between miR-30a-5p expression and survival. C: miRNA expression in primary 
ccRCC and matched metastatic specimens. miR-124 and -30a-5p were downregulated with 4.16 and 5.98 folds (p = 0.09 and p = 0.046). 
miR-200c-3p was overexpressed in metastases compared to the primary tumors (105 fold change; p < 0.0001).Columns and bars represent 
mean±SD, Stars (*) indicate statistical significance (p < 0.05).
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Next, we examined the association of these 
miRNAs’ expression and survival on an individual sample 
set of 62 cases of primary ccRCC and we compared the 
expression of these miRNAs in matched pairs of primary 
and metastatic ccRCC from the same patients
Higher expression of miR-124-3p was significantly 
associated with longer overall survival (HR:2.6; p 
= 0.032). This is in line with the tendency of lower 
expression of miR-124-3p (fold change: -4.61, p = 0.09) 
in metastatic tumors compared to primary ccRCC (Figure 
2). Results did not reach statistical significance, probably 
due to the small sample size. 
Interestingly, miR-200c-3p showed statistically 
significant higher expression in metastatic compared 
to primary tumors (fold change: 104.9, p < 0.001). 
miR-200c-3p showed an opposite pattern with higher 
expression levels associated with lower disease-free 
and overall survival, although this was not statistically 
significant.
There was no significant association between 
miRNA-30a-5p expression and survival (Figure 2). There 
was a tendency of lower expression of miR-30a-5p (fold 
change: -5.99, p = 0.07) in metastatic tumors compared to 
primary ccRCC.
We further validated our findings using an 
independent patient cohort from the TCGA database. 
Comparable results were obtained for all three miRNAs 
(Supplementary Figure 1).
The global effect of miR-124-3p, miR-30a-5p and 
miR-200c-3p dysregulation
We hypothesized that miRNAs (nodes) with the 
highest number of miRNA-target interactions (edges) will 
have the most significant effect on RCC pathogenesis. 
miR-200c-3p, miR-124-3p and miR-30a-5p were the most 
connected with 7-9 targets each. These were selected for 
further experimental validations. In order to investigate 
the functional impact of these miRNAs, we transfected 
all three miRNA mimics into 786-O and Caki-2 kidney 
cancer cell lines. Cell lines had been previously tested 
and showed relatively low expression of these miRNAs, 
and successful transfection was confirmed by RT-qPCR 
analysis (Supplementary Figure 2). We compared global 
gene expression before and after all three miRNAs co-
transfection using microarray analysis. Significantly 
deregulated genes were subjected to IPA pathway 
analysis. The mostly altered pathways were “Molecular 
mechanism of cancer”, ”Integrin signaling”, ”Cell cycle”, 
and ”Regulation of the epithelial-mesenchymal transition 
pathway” (Supplementary Table 3). To gain more insight 
to the functional impact of these three miRNAs on ccRCC, 
we performed GO analysis of the genes significantly 
regulated as the result of triple transfection of these 
miRNAs. The most significantly altered functions were 
”locomotion” and functional groups related to migration 
(such as ”cell adhesion”, ”cell motility”, ”cell-cell junction 
organization”, ”negative regulation of cell adhesion”. In 
order to examine if these three miRNAs are major players 
in ccRCC pathogenesis, we compared, using Gene 
Ontology (GO) analysis, our ccRCC miRNA network 
Figure 3: Gene Ontology (GO) analysis of ccRCC upon the effect of miR-124-3p, -30a-5p and -200c-3p. A: Functional 
gene ontology clustering of ccRCC miRNA-target network members. b: Functional gene ontology analysis of miR-124, miR-30a-5p and 
miR-200c-3p targets evaluated by transcriptome profiling following triple-miRNAtransfection in 786-O and Caki-2 cells. Circles represent 
GO enriched categories. Colours and axis Y indicate log10(Benjamini-Hochberg FDR q-values).
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targets to the targets of these three miRNAs, as revealed 
by microarray analysis. As shown in Figure 3, there was 
a significant overlap in functional annotations of the two 
groups, indicating that these three miRNAs can be cardinal 
players in ccRCC pathogenesis.
These functions were further experimentally 
validated by PCR array analysis of the genes involved in 
extracellular matrix and cell adhesion pathways. Predicted 
targets of miR-124-3p were significantly downregulated 
upon its overexpression (Supplementary Figure 3). 
Overall, there was also a significant alteration in ECM and 
adhesion pathway signaling before and after miR-124-3p 
transfection (p <0.05) (Data not shown).
Overall effect of miR-124-3p, miR-200c-3p, and 
miRNA-30a-5p on ccRCC cell migration, invasion 
and proliferation
GO analysis indicated that these miRNAs were 
involved in cell migration and invasion. We experimentally 
tested this by transwell migration and invasion assays 24 
hours following miRNA mimics transfection. Restoration 
of levels of any of the three miRNAs decreased the 
transwell migration and invasion in 786-O cells (Figure 4). 
Overexpression of all three miRNAs significantly reduced 
migration and invasion of 786-O and Caki-2 cells, except 
miR-30a-5p which did result in significant reduction of 
Caki-2 cell invasion (Figure 4).
To further validate our results, we tested the effect of 
miR-124-3p on cell migration using wound healing assay. 
Hydroxyurea was used to inhibit proliferation. As shown 
in Figure 4, miR-124-3p transfection resulted in significant 
reduction of the rate of cell migration.
We also assessed the effect of these miRNAs 
on cell proliferation/viability using WST-1 metabolic 
assay. Co-transfection of all three miRNAs at a 30 nM 
final concentration resulted insignificant decrease of 
cell proliferation/viability in 786-O, Caki-2 and ACHN 
kidney cancer cell lines. When individually transfected 
(30 nM), only miR-124 resulted in a small but significant 
decrease in cell proliferation in metastatic Caki-2 and 
ACHN cells. In the 786-O cells, there was a decrease in 
cell proliferation although this did not reach statistical 
significance (Figure 5A). Using MTT assay, miR-124-3p 
overexpression resulted in a slight decrease in the rate of 
cell proliferation. This did not, however, reach statistical 
significance (Supplementary Figure 4).
Evaluation of individual miR-124 and miR-30a-5p 
function by gene expression profiling
Next, we wanted to zoom in to the specific functions 
of each of these three miRNAs. miR-200c-3p is a well-
known tumor suppressor and as a member of miR-200 
family controls epithelial-mesenchymal transition. Its 
role already has been documented in ccRCC [11, 12]. 
Therefore we selected miR-124-3p and miR-30a-5p for 
further investigation.
We first examined the effect of overexpression of 
each of these miRNAs on gene expression profile in the 
786-O primary ccRCC cells using microarray analysis. 
miR-30a-5p overexpression resulted in significant 
alterations in a number of pathways including ”Cyclins and 
Cell Cycle Regulation” and ”Regulation of the Epithelial-
Mesenchymal Transition Pathway” (Supplementary Table 
4A). GO analysis showed the involvement of ”regulation 
of transcription” and ”TGF-β signaling” among others 
(Supplementary Table 4B).
For miR-124-3p, the most significant pathways 
were those related to migration and invasion, such as 
”Regulation of Cellular Mechanics by Calpain Protease”, 
„Integrin signaling”, „Regulation of the Epithelial-
Mesenchymal Transition Pathway”, „Actin Cytoskeleton 
Signaling”, „Epithelial Adherens Junction Signaling”, 
„Paxillin Signaling”, „Remodeling of Epithelial Adherens 
Junctions” (Supplementary Table 5A). Additionally, 
„Renal cell carcinoma signaling” and cell cycle-related 
pathways including ”G1/S Checkpoint Regulation” 
and ”Cyclins and Cell Cycle Regulation” were also 
significantly altered after miR-124-3p transfection. miR-
124-3p targets in these pathways include MET (MET 
proto-oncogene, receptor tyrosine kinase), RRAS and 
RRAS2 (related RAS viral (r-ras) oncogene homolog 
and 2),GRB2 (growth factor receptor-bound protein 2), 
TGFB1 (transforming growth factor, beta 1) and RAP1A 
(RAP1A, member of RAS oncogene family). Similar 
results were obtained by GO analysis, where the most 
significant GO Biological Processes were „regulation of 
cellular component movement”, „nucleoside metabolic 
process” and „cell junction organization” (Supplementary 
Table 5B). As we already assessed cell migration and 
invasion after miR-124-3p mimics transfection as shown 
above, we investigated miR-124-3p influence on cell cycle 
and proliferation as a next step.
miR-124-3p effect on cell cycle and proliferation
Despite we found the alteration of cell cycle 
and proliferation at transcriptional level assessed by 
microarray we could not clearly prove significant miR-
124-3p effect on cell proliferation using two different 
metabolic assays. Therefore we performed flow cytometry, 
a more sensitive approach investigating miR-124-3p effect 
on cell cycle and proliferation.
We found an average 5% and 2% decrease in S 
phase and an average 10% and 5% decrease in G2M phase 
in 786-O and ACHN cells following 30 nM miR-124-3p 
transfection, however only S phase decrease was proved 
to be statistically significant in ACHN cells (Figure 5B-
5C). Using CFSE flow cytometry proliferation assay, all 
three cell lines showed a small but significant decrease of 
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Figure 4: miR-124-3p, -30a-5p and -200c-3p effect on migration and invasion of kidney cancer cell lines. A: miRNA 
effect on transwell migration and invasion of 786-O and Caki-2 cells. miR-124-3p, -30a-5p and 200c-3p overexpression decreased 786-O 
cells migration by 40%, 39% and 47%, respectively (p < 0.001), and reduced Caki-2 cell migration by 68%, 28% and 66%, respectively 
(p < 0.001). miR-124-3p and miR-200c-3p decreased cell invasion by 55% and 61%, respectively (p < 0.001) in 786-O cells and by 74% 
and 77% (p < 0.001) in Caki-2 cells. miR-30a-5p also inhibited invasion of 786-O cells by 35% (p < 0.001) but had no significant effect 
on Caki-2 cells (p = 0.07). Columns and bars represent mean±SEM. b: Representative photomicrographs showing the effect of miR-124-
3p overexpression on the migration rate of the 786-O RCC cell line. The top row shows the cells at the time of wounding (0 h), and the 
bottom row shows cellular migration after 6 hours. Overexpression of miR-124-3p significantly decreased the rate of cell migration, with 
incomplete wound closure after 6h, compared to controls. Representative bar graph showing the effect of miR-124-3p on cellular migration.
Oncotarget12549www.impactjournals.com/oncotarget
Figure 5: miR-124-3p, -30a-5p and -200c-3p effect proliferation and cell cycle. A: Triple-miRNA transfection decreased 
cell proliferation/viability by 29.91%, 27.05% and 26.64% in 786-O, Caki-2 and ACHN cells using WST-1 assay. Individual miR-124-3p 
transfection also inhibited proliferation/viability of Caki-2 and ACHN cells by 18.12% and 24.75%.Columns and bars represent mean±SD, 
b: miR-124-3p mimic effect on cell cycle assessed by flow cytometry analysis. Representative pictures of cell cycle phase distribution after 
transfection with either Non-targeting Control or miR-124-3p mimic in different kidney cancer cell lines. c: normalized average dG1G0, 
dS and dG2M distribution (N = 3). d: miR-124-3p effect on proliferation investigated by CFSE flow cytometry analysis. Representative 
normalized CFSE dilution after transfection with averaged proliferation index, PI (N = 3). Data are presented as means of average percentage 
of cells ± SD. Stars (*) indicate statistical significance (p < 0.05), ns: non-significant.
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proliferation index and present lower generation numbers 
after miR-124-3p transfection (Figure 5D).
target validation
Because miR-124-3p accomplished only a slight 
effect on cell proliferation next we focused its influence 
on migration/invasion processes. To understand the 
mechanism by which miR-124-3p can affect tumor cell 
migration and invasion, we selected two targets of miR-
124-3p involved in cell migration-invasion for further 
validation. Caveolin 1 (CAV1) was downregulated by 
microarray with -4.59 and -8.00 fold change (p < 0.001 
and =0.007) following miR-124-3p transfection, and it was 
involved in pathways related to migration (Supplementary 
Table 5A). Flotillin 1 (FLOT1) is documented in the 
literature to be implicated in cell migration and was a 
validated target of miR-124-3p in breast cancer [13]. We 
Figure 6: cAV1 and Flot1 protein expression and association with survival in clinical specimens and validation as 
miR-124-3p targets. miR-124-3p targets expression in ccRCC. Scatter plots show CAV1 (A) and FLOT1 (b) protein expression in 23 
matched ccRCC vs. normal kidney specimens with representative western blot images. CAV1 and FLOT1 were upregulated with 21 and 
1.5 folds, respectively (p < 0.01 and p = 0.03) in tumour tissues compared to their matched normals. c: miR-124-3p transfection resulted in 
CAV1 mRNA downregulation with 3.9, 5.8 and 5.11 folds (p < 0.001) in 786-O, ACHN and Caki-2 cells, respectively. FLOT1 expression 
was also reduced but this did not reach statistical significance. d-e: Both CAV1 and FLOT1 protein were downregulated following miRNA 
transfection by 52%, 55%, 66% (p < 0.001) and 39%, 48%, 44% (p < 0.05) in 786-O, ACHN and Caki-2 cells, respectively. F-G: Kaplan-
Meier analysis showing that higher CAV1 or FLOT1 expressions are associated with worse survival of ccRCC patients. Columns and bars 
represent mean±SD, stars (*) indicate statistical significance (p < 0.05).
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investigated CAV1 and FLOT1 protein expression by 
Western blot in 23 pairs of normal-ccRCC specimens, and 
found CAV1 protein to be upregulated with an average 
20.8 fold and FLOT1 with 1.47 fold in ccRCC compared 
to normal counterparts form the same patient (Figure 6A-
6B). As miRNAs having a so-called fine tuning effect 
on the target expression 1,47 fold change on protein 
level can be resulted as a miRNA effect. In many cases 
miRNAs do not lead to expression change on mRNA level 
but only on protein level. To include these possibilities 
as well we selected FLOT1 as a potential second target 
beside CAV1. We further assessed the effect of miR-
124-3p overexpression on these two targets at the mRNA 
level (by RT-qPCR) and protein level (by Western blot 
analysis) in 786-O, ACHN and Caki-2 cell lines. miR-
124-3p overexpression resulted in a significant reduction 
of the expression of CAV1 at the mRNA level (Figure 6C) 
and the expression of CAV1 and FLOT1 at protein level 
(Figure 6D-6E).
We also investigated the association between patient 
survival and CAV1, FLOT1 expression. Compared to 
miR-124-3p, opposite pattern was seen with CAV1 and 
FLOT1: higher expression associated with worse overall 
survival of ccRCC patients (HR:0.697; p = 0.0325 and 
HR:0.483; p < 0.001) (Figure 6F-6G).
To further examine if the effect of miR-124-3p 
can be mediated through CAV1 and FLOT1, we tested 
the effect of knocking down of these two molecules (by 
siRNAs) on cell migration. CAV1 and FLOT1 siRNA 
knock down resulted in a similar effect on cell migration, 
suggesting that miR-124 effect can be mediated through 
these targets (Supplemetary Figure 5).
dIscussIon
To identify the most significant miRNAs and to 
understand their contribution to ccRCC, we constructed 
a miRNA-gene interaction network. Because target 
prediction is not always accurate, we added a number 
of unique features to improve accuracy of our network, 
including using tissue-specific target prediction, and 
filtering the targets for “RCC associated genes”. We 
identified miR-124-3p, -30a-5p and -200c-3p as the most 
influential miRNAs by having the highest number of 
interactions. The downregulation of these miRNAs is in 
keeping with previous results from our lab and others [5]. 
We also recognized their roles in aggressive/metastatic 
behaviour by in vitro migration and invasion assays and 
gene expression profiling.
Based on our findings miR-124-3p is a tumor 
suppressor miRNAs as it is downregulated in ccRCC 
compared to normal kidney; and patients having lower 
miR-124-3p expression demonstrate worse disease-free 
and overall survival. Also miR-124-3p shows a tendency 
of lower expression in metastatic specimens compared 
to primary tumors. This is further confirmed by our 
experimental evidence showing its significant suppressor 
effect on migration, invasion and a slight effect on 
proliferation of different type of kidney cancer cell lines.
Interestingly miR-200c-3p showed an opposite 
correlation to patient survival, where patients having 
higher expression had worse DFS and OS. This can be 
related to the fact that in metastatic samples miR-200c-
3p showed higher expression compared to primary 
tumors. Other studies, however, showed that miR-200c-
3p decreases the metastatic ability of renal carcinoma 
cells by upregulating E-cadherin through ZEB1 [14, 
15, 5]. Thus the involvement of miR-200c-3p in tumor 
progression needs to be investigated further. miR-30a-
5p inhibited migration and invasion of 786-O primary 
cells and migration of the metastatic Caki-2 cells, and 
this correlated with its lower expression in metastatic 
compared to primary tumors. Overall, our results show 
that these three miRNAs together can possibly have a key 
role in ccRCC.
To our knowledge, this is the first report validating 
CAV1 and FLOT1 as miR-124-3p targets in ccRCC. 
We also showed that these proteins are overexpressed 
in ccRCC and patients having higher CAV1 and FLOT1 
expression present worse overall survival, with an inverse 
correlation to the survival outcome of miR-124-3p which 
emphasizes the role of the miRNA in controlling them.
Our results showing miR-124 downregulation in 
cancer is not unprecedented. miR-124 was reported as 
tumor suppressor miRNA in several cancers including 
prostate, bladder, breast, colorectal, nasopharyngeal, 
gastric, pancreatic or hepatocellular cancers. It was 
documented to target Collagen prolyl-hydroxylases 
[16], ROCK1 (Rho-associated, coiled-coil containing 
protein kinase 1) [17], ETS1 (v-ets avian erythroblastosis 
virus E26 oncogene homolog 1) [18], KITENIN (KAI1 
C-Terminal Interacting Tetraspanin) [19], FOXQ1 
(forkhead box Q1) [20], EZH2 (enhancer of zeste 2 
polycomb repressive complex 2 subunit) [21], RAC1 (rho 
family, small GTP binding protein Rac1) [22] or STAT3 
(signal transducer and activator of transcription 3) [23]. 
Majority if not all of these molecules are implicated in 
cell migration-invasion and proliferation. In glioma and 
pancreatic cancer, the connection between miR-124 
downregulation and worse patient survival were also 
reported [22, 24].
CAV1 and FLOT1 were also shown to affect 
migration and invasion in porcine kidney epithelial cells 
and breast cancer [13, 25]. CAV1 is a main component of 
the plasma membrane caveolae and influence caveolae-
mediated endocytosis [26]. Caveolin-1 can induce 
lamellipodia formation via an Akt-dependent pathway 
[27], implying its role in cell migration and invasion. 
It also functions as a membrane adaptor to link the 
integrin alpha subunit to the tyrosine kinase Fyn. Upon 
integrin ligation, Fyn is activated and promotes cell cycle 
progression through Ras-ERK pathway [28]. CAV1 also 
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inhibits anoikis, a form of programmed cell death which 
is induced by anchorage-dependent cells detaching [29]. It 
is frequently overexpressed in different neoplasms such as 
prostate [30], bladder [31], and pancreatic cancers [32]. In 
ccRCC, it was reported to be overexpressed [33, 34], and 
to be associated with poor prognosis [35].
Flotillin-1 (FLOT1), similarly to CAV1 is also 
related to endocytosis and vesicular trafficking [36]. It was 
found to upregulated in several types of cancer as breast 
[37], esophageal [38], hepatocellular [39] and non-small 
cell lung cancer [40]. FLOT1 upregulation was associated 
with tumor progression and patient survival. Recently 
it was found that FLOT1 has a direct role in epidermal 
growth factor (tyrosine kinase) receptor activation and 
the latter MAP kinases activation [41] which can explain 
its oncogenic role in tumorous tissues. During the 
manuscript preparation, a report was published showing 
that higher expression of FLOT1 is associated with cancer 
progression and poor patient survival in ccRCC [42] 
which is consistent with our results. It should be also noted 
that there are other important targets and pathways that 
merit investigation in future studies.
In conclusion, we provide evidence showing the 
presence of a miRNA-target network that significantly 
contributes to ccRCC pathogenesis. miR-124-3p, -30a-
5p and -200c-3p are key miRNAs participating in ccRCC 
aggressive/metastatic behaviour; and miR-124-3p has 
a key role in this - at least in part - through regulating 
CAV1 and FLOT1 expression. Restoration of the levels of 
these tumor suppressor miRNAs could be considered as a 
potential therapeutic strategy for RCC.
MAterIAls And Methods
datasets and network construction
Using our previously assembled data (1531 and 49 
most significantly dysregulated genes and miRNAs in 
ccRCC [10]) based on 593 ccRCC and 389 normal kidney 
specimens, we performed tissue-specific target prediction 
as previously described [9]. In order to ascertain the 
role of miRNAs in ccRCC pathogenesis we filtered the 
target genes for the term “RCC associated genes” using 
Ingenuity Knowledge Database, which is a curated 
database having over 10.000 peer-reviewed citations 
(http://www.ingenuity.com/products/ipa) and contains 
genes have previously been described as altered related to 
RCC. We visualized our network using Cytoscape 3.1.0. 
software, mapping node’s colour and size to degree and 
edge’s color and size to edge betweeness. Betweeness 
centrality of an edge is the sum of the fraction of all-pairs 
shortest paths that pass through it. An edge with high 
edge betweeness centrality score represents a bridge-like, 
or bottleneck connector between different parts of the 
network.
Validation set patient cohorts
The study was approved by the Research Ethics 
Board of St. Michael′s Hospital. Retrospectively 
formalin-fixed, paraffin-embedded (FFPE) tumor 
samples of 62 ccRCC patients were obtained from St. 
Michael’s Hospital and analyzed for miRNA expression. 
6 primary and metastatic matched FFPE specimen pairs 
were investigated. Additionally fresh tissue of 23-23 
paired normal kidney and ccRCC specimens were also 
collected for protein analysis. Routine histopathology 
diagnoses were confirmed by 2 independent pathologists. 
Descriptive statistics of the patient cohort is described in 
Supplementary Table 6.
Validation on TCGA database
We also validated our results using the publicly 
available ccRCC dataset of The Cancer Genome Atlas 
(TCGA), retrieving the survival data through the cBio 
Cancer Genomics Portal. In total, we downloaded and 
analysed 499 ccRCC and 66 normal samples miRNA 
sequencing data. To compare the miRNA expression 
T-test with Welch correction was used by GraphPad Prism 
software. In total, data of 425 patients were available for 
analysis. Optimal cut off values were identified using 
method “outcome euclidean” algorithm by CutoffFinder 
[43], survival data was then analysed by the Kaplan-Meier 
method, followed by log-rank test.
mirnA mimics transfection
Primary 786-O and metastatic ACHN and 
Caki-2 kidney cancer cell lines were purchased from 
ATCC. Cells were transfected with 30 nM any of 
miR-124-3p, miR-30a-5p, miR-200c-3p mirVana™ 
miRNA Mimics (ID: MC10691, MC11062, MC11714) 
or with Non-targeting Control miRNA mimic #1 
(#:44640633, Life Technologies, Grand Island, NY, 
USA) using LipofectamineRNAiMAX (#13778075, Life 
Technologies) as previously described [10]. Transfections 
were controlled by RT-qPCR from extracted RNA after 
24h using TaqMan assays (Supplementary Figure 2).
RNA extraction from cell lysate and FFPE 
samples
Total RNA extraction from cells for RT-qPCR and 
microarray analysis was performed using (miRNeasy 
kit, #217004, Qiagen, Mississauga, Canada). For FFPE 
samples RNA isolation was done using six 1 mm cores 
of pure tumor areas of ccRCC and metastases, as we 
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previously described [44] using the miRNeasy FFPE 
Kit (217504, Qiagen, Mississauga, Canada). RNA 
concentrations and quality were determined using 
NanoDrop (Thermo Scientific, Hudson, NH, USA) and 
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, 
USA).
Gene expression profiling by microarray
Two hundred nanograms of total RNA were 
labelled using Illumina TotalPrep-96 RNA Amplification 
kit (PN:4393543, Ambion Life Technologies, Grand 
Island, NY, USA) as per amplification protocol. 750ng 
of cRNA were generated and hybridized into one Human 
HT-12 V4 BeadChip. The BeadChip was incubated at 
58°C, with rotation speed 5 for 18 hrs for hybridization. 
The BeadChip was washed and stained as per Illumina 
protocol and scanned on the iScan (Illumina, San 
Diego, CA, USA). All samples passed Illumina sample 
dependent and independent QC Metrics. Data analysis 
was performed by Genespring GX 12 Software (Agilent 
Tech Inc, Santa Clara, CA, USA). Raw data was filtered 
by percentile (lower cut-off: 20). Fold change filter 
was set to 2-fold, and then unpaired t-test was used to 
identify significant (p < 0.05) gene expression changes 
with multiple testing correction (Benjamini-Hochberg) to 
control the false discovery rate and get statistically reliable 
results. Functional analysis were done by IPA pathway 
analysis and GO categories of miRNA target genes were 
determined using Generic Gene Ontology (GO) Term 
Mapper, which were then submitted to REVIGO [45] for 
further analysis.
taqMan® Array human gene expression assays
We tested the effect of miR-124-3p overexpression 
on extracellular matrix and cell adhesion pathway by 
TaqMan® Array human gene expression assaysusing 
the Step One™ Plus Real-Time PCR System (Applied 
Biosystems). ACHN cells were transfected with miR-124-
3p and compared to cells transfected with a non-targeting 
control miRNA. Total RNA was isolated using the RNeasy 
Mini Kit (Qiagen) according to the manufacture’s protocol. 
Reverse transcription was done by using High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). This was followed by performing 
PCR amplification using the TaqMan® Array human 
gene expression assays specific for human extracellular 
matrix and cell adhesion molecules. Fold change was 
calculated by 2(-ΔΔCt). First ΔCt were calculated for each 
target by normalizing its threshold cycle to the average 
of endogenous controls including 18S, GAPDH, HPRT1, 
GUSB,RPLP0 and PPIA.Then ΔΔCt was calculated as 
follows ΔΔCt = [ACHNcells transfected with miR-124-
3pΔCt - ACHN cells transfected with a non-targeting 
control miRNAΔCt].
RT-qPCR of miRNAs and miRNA target genes
For miRNA analyses, reverse transcription was 
performed with 1 ng total RNA using the TaqMan 
MicroRNA Reverse Transcription Kit; miRNA expression 
was measured on Viia 7 Real-Time PCR System (Life 
Technologies, Grand Island, NY, USA) with TaqMan 
microRNA Assays for miR-124-3p, miR-30a-5p and 
miR-200c-3p (Assay ID: 001182, 000417, 002300) 
as previously described [46]. Relative expression was 
determined using the ddCt method and expression values 
were normalized to the geometric mean of RNU44 and 48 
(Assay ID: 001094, 001006) [44, 47]. miRNA expression 
comparison was carried out by paired T test, survival 
data was analyzed by the Kaplan-Meier method after 
determining cut-offs by CutoffFinder and followed by 
log-rank test.
For evaluation of target genes expression 1 ug total 
RNA was reversed transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies, 
Grand Island, NY, USA). Gene expression was measured 
using Fast Syber Green Master Mix (Life Technologies, 
Grand Island, NY, USA) using the following primers: 
CAV1 F-5′CCGCGACCCTAAACACCTC-3′, 
R-5′GCCTTCCAAATGCCGTCAA-3′; FLOT1 
F-5′ACATTGCCCTGGAGACGTTAG-3′, 
R-5′ACACTGATGCCCATGTTGAC-3′. The 
combination of peptidylprolylisomerase A (PPIA) and 
Tubulin-α (TUBA1A) was used as an endogenous 
control: PPIA, F–5′-ATGCTGGCCCCAACACAA-3′, 
R–5′-CCCTCTTTCACCTTGCCACC-3′; TUBA1A, 
F–5′-TCTTCCACCCTGAGCAACTT-3′, R–5′-
CTCCAGCTTGGACTTCTTGC-3′ as previously 
described [10].
Viability, migration and invasion assays
Following miRNA mimics transfection, viability, 
migration and invasion assays were conducted as 
previously described [48]. Briefly, 48h after 30 nM 
miRNA mimics transfection cell viability and proliferation 
was monitored by WST-1 Cell Proliferation Reagent 
(#05015944001, Roche Applied Science, Indianapolis, 
IN, USA) following the manufacturer’s protocol. Cell 
behaviour was investigated by transwell migration and 
invasion assays (#354578 and #354480, BD-Biocoat, 
Bedford, MA, USA) on 8.0 µm chambers 24 hours 
following transfection as previously published [44]. 
Hydroxyurea was added to inhibit cell proliferation during 
migration and invasion assays. Statistical significance 
was calculated using one-way ANOVA with Bonferroni’s 
multiple comparisons test.
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Migration was additionally assessed by wound 
healing assay. Cells were seeded in a 12 well plate, 
and transfected either with Lipofectamine RNAiMAX 
Transfection Reagent, miR-124-3p, non-targeting control 
miRNA, siRNAs specific for CAV1 (siRNA ID: s2448 
Cat#: 4390824, Life technologies), or FLOT1 (siRNA ID: 
s19915, Cat#: 4392420), or non-targeting control siRNA 
(Cat#: 4390843). Twenty four hours after transfection, the 
cell monolayer was wounded using a 200μL pipette tip. 
Photomicrographs were taken every 30 minutes starting 
at the time of wounding (0 hrs) and continued up to 8 hrs 
using a microscope in an incubation chamber with 37ºC 
and 5% CO2. The microscope was programmed to take 
a series of photomicrographs at the exact place. Image J 
Software (National Institutes of Health, Bethesda, ME, 
http://rsbweb.nih.gov/ij/) was used for cell migration 
analysis. Percent cell-free area was calculated as [(cell-
free area8hrs/cell-free area0hrs) x 100] and cell migration rate 
was displayed as the percent of cell covered area (100 - 
percent cell-free area).
Protein extraction and western blotting
From fresh tissue samples total protein was 
extracted as previously described [49]. Briefly, tissues 
were homogenized using a hand-held homogenizer in ice-
cold phosphate buffered saline (PBS) with 1:100 protease-
inhibitor cocktail (#P3840, Sigma-Aldrich, St Louis, MO, 
USA). Cell debris was then removed by centrifugation (for 
30 min at 4°C, 14,000 rpm), then the supernatant was used 
for analysis.
48h after transfection cells were lysed on ice using 
cold lysis buffer (100 mMNaCl, 30 mM Hepes (pH 7.5), 
20 mMNaF, 1 mM EGTA, 1% Triton X-100, supplemented 
with 1 mM Na3VO4, 1 mM PMSF, and 1:100 protease-
inhibitor cocktail). Protein concentration was determined 
by BCA protein assay (Pierce Biotechnology, Rockford, 
IL, USA). Total protein was separated in 10% SDS–
PAGE, transferred to a nitrocellulose membrane and 
incubated with 1:1000 primary rabbit antibodies (CAV1, 
#3238; Flotillin-1, #3253; Cell Signalling Technology 
Inc., Danvers, MA, USA) overnight. Membranes were 
stripped and re-probed for mouse anti-β-actin (1:1000, 
Cell Signalling Technology Inc.) as a loading control. 
Anti-mouse and anti-rabbit-HRP conjugated IgGs were 
used as secondary antibodies (1:10000, W402B, W401B, 
Promega, Madison, WI, USA). Band intensities were 
quantified using Image J software (Bethesda, MD, USA). 
For comparison of normal and ccRCC samples and for 
calculating p-value the Wilcoxon Signed Ranks Test was 
applied.
Cell cycle analysis
48h following transfection 786-O, Caki-2 and 
ACHN cells were harvested, washed with 1xPBS and 
then fixed with ice cold 70% ethanol for 15 min on ice. 
Cells were then washed with PBS and cell pellet was 
resuspended in 20 mg/ml RNAse A solution (#:LS005649, 
Worthington Biochem, Lakewood, NJ, USA) and 
incubated for 1 hour at 37ºC. Propidium Iodide (#:556463, 
BD BioSciences) was added at a final concentration 50 
ug/ml and incubated overnight at 4oC. DNA content was 
analysed by flow cytometry on a MACS Quant flow 
cytometer (MiltenyiBiotec, Auburn CA) at an event rate 
of < 500 evs/s. Data was analysed using Multicycle AV 
(FCS Express, DeNovo Software, Los Angeles, CA, USA) 
and evaluated for acceptable G1 peak CV and model fit 
chi squared values with appropriate singlet gating to 
exclude coincident events. P-value was calculated using 
the Wilcoxon Signed Ranks Test.
CFSE proliferation analysis
The effect of miR-124-3p on cell proliferation was 
analysed by carboxy fluorescein diacetate succinimidyl 
ester (CFSE, #422701, BioLegend Inc, San Diego, CA, 
USA) dye dilution using flow cytometry as previously 
described [50], with minor modification. Briefly, 786-O, 
Caki-2 and ACHN cells were labelled with CFSE dye 
according to the manufacturer instructions. Cells were 
trypsinized and suspended in in 1xPBS at a 5x106 cells/
ml. Cells were mixed with CFSE at a final concentration 
1 uM for 10 min. Reactions were quenched with 10 ml 
ice-cold complete media and washed twice. Cells then 
were seeded at a density of 4.5x106 cells/60 cm2 dish, and 
transfected 24h later with 30 nM miR-124-3p mimics or 
Non-targeting Control as described above. After 48 h cells 
were trypsinized, washed with PBS and CFSE dilution 
was determined by flow cytometry using a MACS Quant 
(MiltenyiBiotec, Auburn, CA, USA). The acquired data 
were analysed by FCS Express 4 (DeNovo Software, 
Los Angeles, CA, USA) based on live, single cell gates 
followed by proliferation analysis to model the generation 
peaks and proliferation index of each population. P value 
was calculated using the Wilcoxon Signed Ranks Test.
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